Literature DB >> 29778266

Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.

Jagpreet Chhatwal1, Qiushi Chen2, Rakesh Aggarwal3.   

Abstract

Oral direct-acting antiviral agents have revolutionized treatment of hepatitis C virus (HCV) infection. Nonetheless, barriers exist to elimination of HCV as a public health threat including low uptake of treatment, limited budget allocations for HCV treatment, and low awareness rates of HCV status among infected people. Mathematical modeling provides a systematic framework to analyze and compare potential solutions and elimination strategies by simulating the HCV epidemic under different conditions. Such models evaluate impact of interventions in advance of implementation. This article describes key components of developing an HCV burden model and illustrates its use by simulating the HCV epidemic in the United States.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; Direct-acting antivirals; Health economics; Hepatitis C elimination; Markov modeling; Public health; Simulation

Mesh:

Substances:

Year:  2018        PMID: 29778266     DOI: 10.1016/j.idc.2018.02.008

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  8 in total

Review 1.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

2.  A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China.

Authors:  Madeline Adee; Yueran Zhuo; Tiannan Zhan; Qiushi Chen; Asmae Toumi; Turgay Ayer; Chizoba Nwankwo; Huaiyang Zhong; Amy Puenpatom; Jagpreet Chhatwal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

3.  Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.

Authors:  Jagpreet Chhatwal; Qiushi Chen; Xiaojie Wang; Turgay Ayer; Yueran Zhuo; Naveed Z Janjua; Fasiha Kanwal
Journal:  JAMA Netw Open       Date:  2019-05-03

4.  Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.

Authors:  Qiushi Chen; Turgay Ayer; Emily Bethea; Fasiha Kanwal; Xiaojie Wang; Mark Roberts; Yueran Zhuo; Stefano Fagiuoli; Jorg Petersen; Jagpreet Chhatwal
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

5.  Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.

Authors:  A Blythe Ryerson; Sarah Schillie; Laurie K Barker; Benjamin A Kupronis; Carolyn Wester
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-10       Impact factor: 17.586

6.  Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016.

Authors:  Eli S Rosenberg; Elizabeth M Rosenthal; Eric W Hall; Laurie Barker; Megan G Hofmeister; Patrick S Sullivan; Patricia Dietz; Jonathan Mermin; A Blythe Ryerson
Journal:  JAMA Netw Open       Date:  2018-12-07

7.  1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease.

Authors:  Abdelsattar M Omar; Mahmoud A Elfaky; Stefan T Arold; Sameh H Soror; Maan T Khayat; Hani Z Asfour; Faida H Bamane; Moustafa E El-Araby
Journal:  Biomolecules       Date:  2020-03-21

8.  Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016.

Authors:  Heather Bradley; Eric W Hall; Elizabeth M Rosenthal; Patrick S Sullivan; A Blythe Ryerson; Eli S Rosenberg
Journal:  Hepatol Commun       Date:  2020-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.